14-day Premium Trial Subscription Try For FreeTry Free

Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of QURE
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Tuesday for uniQure N.V.
(Updated on Apr 23, 2024)

Sell candidate since Feb 29, 2024 Loss -17.39% PDF

The uniQure N.V. stock price fell by -1.45% on the last day (Tuesday, 23rd Apr 2024) from $4.82 to $4.75. During the last trading day the stock fluctuated 3.38% from a day low at $4.74 to a day high of $4.90. The price has fallen in 7 of the last 10 days and is down by -8.65% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -64 thousand shares and in total, 314 thousand shares were bought and sold for approximately $1.49 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -16.06% during the next 3 months and, with a 90% probability hold a price between $3.62 and $5.06 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

QURE Signals & Forecast

A buy signal was issued from a pivot bottom point on Wednesday, April 17, 2024, and so far it has risen 1.71%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The uniQure N.V. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $5.07. On a fall, the stock will find some support from the short-term average at $4.72. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss for uniQure N.V. stock

uniQure N.V. finds support from accumulated volume at $4.74 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.160 between high and low, or 3.38%. For the last week the stock has had daily average volatility of 3.24%.

uniQure N.V. is oversold on RSI14 (23). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (QURE) For The Upcoming Trading Day Of Wednesday 24th

For the upcoming trading day on Wednesday, 24th we expect uniQure N.V. to open at $4.79, and during the day (based on 14 day Average True Range), to move between $4.53 and $4.97, which gives a possible trading interval of +/-$0.224 (+/-4.72%) up or down from last closing price. If uniQure N.V. takes out the full calculated possible swing range there will be an estimated 9.44% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $4.74 (0.21%) than the resistance at $5.17 (8.84%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is uniQure N.V. stock A Buy?

uniQure N.V. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.720 Sell Candidate Unchanged

Predicted Opening Price for uniQure N.V. of Wednesday, April 24, 2024

Fair opening price April 24, 2024 Current price
$4.79 ( 0.91%) $4.75

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for QURE

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.95 4.28 %
R2 4.89 2.99 %
R1 4.85 2.20 %
Current price: 4.75
Support S1 4.73 -0.374 %
S2 4.69 -1.17 %
S3 4.63 -2.46 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.75 21.05 %
R2 5.32 12.00 %
R1 5.17 8.84 %
Current price 4.75
Support S1 4.74 -0.211%
S2 4.71 -0.84%
S3 4.67 -1.68%

FAQ

What is the symbol for uniQure N.V. Stock and on which exchange is it traded?
The symbol for uniQure N.V. is QURE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell uniQure N.V. Stock?
uniQure N.V. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy uniQure N.V. Stock?
uniQure N.V. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy uniQure N.V. Stock.

What's the current price of uniQure N.V. Stock?
As of the end of day on the Apr 23, 2024, the price of an uniQure N.V. (QURE) share was $4.75.

What is the 52-week high and low for uniQure N.V. Stock?
The 52-week high for uniQure N.V. Stock is $22.48 and the 52-week low is $4.61.

What is the market capitalization of uniQure N.V. Stock?
As of the Apr 23, 2024, the market capitalization of uniQure N.V. is 227.232M.

When is the next earnings date for uniQure N.V.?
The upcoming earnings date for uniQure N.V. is May 14, 2024.
Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT